UroVysion Results Predict Post-BCG Bladder Cancer Outcomes
Positive results before BCG treatment and at the 6-week instillation are associated with an increased likelihood of disease recurrence and/or progression, study found.
|The following article is part of conference coverage from the 2018 American Urological Association meeting in San Francisco. Renal and Urology News' staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from AUA 2018.|
SAN FRANCISCO—The UroVysion test may enable clinicians to predict which patients receiving initial bacillus Calmette-Guérin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) are more likely to experience disease recurrence and/or progression, according to study findings presented at the American Urological Association 2018 annual meeting.
Yair Lotan, MD, of the University of Texas Southwestern Medical Center in Dallas, and colleagues evaluated the association between findings from the UroVysion assay, which is used to detect chromosomal abnormalities associated with bladder cancer, and risk of disease recurrence or progression in 151 patients who initiated BCG therapy for primary high-grade Ta-T1 tumors, carcinoma in situ, or recurrent NMIBC.
A total of 37 recurrences and 9 progressions occurred. At baseline (prior to initial BCG instillation), 65 patients (43.9%) had a positive UroVysion test. Patients with a positive UroVysion assay at baseline or at the 6-week instillation were significantly more likely to experience recurrence and/or progression at 6 and 9 months. Results showed that 43.1% of patients with a positive test at baseline experienced recurrence and/or progression at 6 months compared with 15.7% of those with a negative test. The proportions were 44.6% vs 20.5%, respectively, at 9 months.
Among patients who had UroVysion results at the time of the 6-week instillation, 43.9% and 43.9% of those with a positive result experienced recurrence and/or progression at 6 and 9 months, respectively, compared with 19.3% and 23.9% of patients with a negative test.
Dr Lotan said the findings could be used to guide patient management and clinical trial enrollment.
Lotan Y, Messing E, Inman B, et al. Evaluation of the UroVysion test in predicting recurrence and/or progression of disease in patients receiving initial BCG for primary high grade Ta-T1 and CIS urothelial carcinoma of the bladder. Data presented in poster format at the American Urological Association 2018 annual meeting, San Francisco, May 18–21. Abstract MP08-14.